Generex Biotech Corp
Seite 2 von 21 Neuester Beitrag: 25.04.21 00:09 | ||||
Eröffnet am: | 11.01.06 11:03 | von: schibi | Anzahl Beiträge: | 515 |
Neuester Beitrag: | 25.04.21 00:09 | von: Brigittevqkfa | Leser gesamt: | 140.819 |
Forum: | Hot-Stocks | Leser heute: | 42 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 21 > |
Anfang Q2 gehts los.
Wer auf dem VerSCHIBIbahnhof steht, der hat halt Pesch.
positv zu beurteilen. Mein Tip: 2stelliger Kurs für dieses Jahr!
Bei Oral-lyn sehe ich das größte Potenzial ;-)
Bin investiert.
TORONTO -- (MARKET WIRE) -- 03/15/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today additional preliminary results (10 weeks) of a long-term (six month) clinical trial of Generex Oral-lyn, the Company's proprietary oral insulin spray product, in adolescent and young adult patients with Type-1 diabetes mellitus. This data, which complements the positive data announced by the Company on March 8, 2006, shows the variations of glycosylated hemoglobin (HbA1c), a very well-known marker for monitoring diabetes, during the first 10 weeks of the study.
Glycosylated hemoglobin (HbA1c) is considered by regulatory agencies and endocrinologists as the best long-term measure of metabolic control of diabetes. "HbA1c correlates with the level of risk for diabetes complications," said Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs. "The continuous and dramatic reduction seen in these preliminary results bode well for patients with diabetes, and society generally, in reducing the burdens of diabetes and its complications."
The investigators concluded that, during the first 10 weeks of this ongoing six-month trial, replacement of subcutaneous injections of regular insulin by Generex Oral-lyn at lunchtime in adolescent and young adult patients with Type-1 diabetes was associated with overall adequate glycemic control and similar glycosylated hemoglobin (HbA1c) concentrations.
Durch H5N1 werden andre Marktteilnehmer aufmerksam auf GNBT.
Von H5N1 spricht vielleicht in 6 Monaten keiner mehr, aber GNBT ist durch.
Heute an der NASDAQ über 22 Mio. Umsatz!!! Da geht was ab!
============================================
GNBT: Awarded Patent in Mexico for Drug Delivery Technology
Generex Biotechnology Corporation (GNBT) has been granted a patent by the Mexico National Registry of Patents titled "Proteinic Drug Delivery System Using Aerosolized Membrane-Mimetic Amphiphiles." The patent relates to an improved delivery system for the administration of large-molecule pharmaceuticals, particularly through the oral and nasal membranes. The patent covers formulations for the delivery of peptidic drugs, vaccines, and hormones and enhances the Company's existing drug delivery platform patent portfolio.
1. Euro-Rallye (zugetroffen)
2. Gewinnmitnahmen (nicht wirklich ;-)
und wollte günstiger wieder rein. Naja, das war wohl nix.
Grüße vom Abschibigleis
Auch die Generex ist dabei.
http://www.usa-aktienprofi.de/realtime.htm